Biogen Idec Inc (BIIB): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Biogen Idec ( BIIB) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.4%. By the end of trading, Biogen Idec rose $1.76 (1%) to $174.14 on average volume. Throughout the day, 1.1 million shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock ranged in a price between $171.42-$174.21 after having opened the day at $171.85 as compared to the previous trading day's close of $172.38. Other companies within the Health Care sector that increased today were: CombiMatrix Corporation ( CBMX), up 18.2%, Cardiovascular Systems ( CSII), up 16.6%, Simcere Pharmaceutical Group ( SCR), up 16.2%, and Fonar Corporation ( FONR), up 11.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $40.52 billion and is part of the drugs industry. The company has a P/E ratio of 29.8, above the S&P 500 P/E ratio of 17.7. Shares are up 17.1% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, AEterna Zentaris ( AEZS), down 22.5%, Spherix ( SPEX), down 11.6%, Sunesis Pharmaceuticals ( SNSS), down 8.6%, and Affymax ( AFFY), down 8.5%, were all laggards within the health care sector with Medivation ( MDVN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

null

More from Markets

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge